Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 4/20 | 0.58 |
| ▸ | BIRC5 | O15392 | 1/20 | 0.51 |
| ▸ | ACHE | P22303 | 9/20 | 0.51 |
| ▸ | BCHE | P06276 | 7/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | EGFR | P00533 | 3/20 | 0.45 |
| ▸ | KDR | P35968 | 2/20 | 0.45 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.45 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.45 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.45 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.45 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.45 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | DRD1 | P21728 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5780726 | 0.93 | ALDH1A1 (0.55) | MCHR1BIRC5ACHEBCHEALDH1A1 | |
| SCHEMBL4010138 | 0.82 | KDR (0.54) | MCHR1BIRC5ALDH1A1EGFRKDR | |
| SCHEMBL5132224 | 0.81 | MCHR1 (0.59) | MCHR1 | |
| SCHEMBL27221098 | 0.80 | BIRC5 (0.59) | MCHR1BIRC5ACHEBCHEALDH1A1 | |
| SCHEMBL12239202 | 0.79 | GAA (0.56) | ALDH1A1 | |
| SCHEMBL13811407 | 0.79 | BIRC5 (0.45) | MCHR1BIRC5ALDH1A1DRD2DRD1 | |
| SCHEMBL14985014 | 0.79 | HTR7 (0.50) | MCHR1ACHEBCHEALDH1A1EGFR | |
| SCHEMBL3859527 | 0.79 | GAA (0.61) | MCHR1BIRC5ACHEBCHEALDH1A1 | |
| SCHEMBL12845311 | 0.79 | BIRC5 (0.66) | MCHR1BIRC5ACHEBCHEALDH1A1 | |
| SCHEMBL8015816 | 0.78 | MCHR1 (0.70) | MCHR1ACHEBCHEKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040063686-A1 | Carboxamide compounds and their use as antagonists of a human 11cby receptor | JOHNSON CHRISTOPHER NORBERT (GB) | 2004-04-01 | — | — | US | disclosed |
| EP-1305304-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS ANTAGONISTS OF A HUMAN 11CBY RECEPTOR | SMITHKLINE BEECHAM PLC (GB) | 2003-05-02 | — | — | EP | disclosed |
| WO-2002010146-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS ANTAGONISTS OF A HUMAN 11CBY RECEPTOR | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063686-A1 | Carboxamide compounds and their use as antagonists of a human 11cby receptor | CNR1, GPR3, CCKAR | MCHR1 133/4885BIRC5 4445/4885ACHE 1228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.